{"id":"NCT00847145","sponsor":"Novartis Vaccines","briefTitle":"Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers","officialTitle":"A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2009-02-19","resultsPosted":"2015-03-03","lastUpdate":"2015-03-03"},"enrollment":2249,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"1a - rMenB+OMV NZ and routine vaccines","otherNames":[]},{"type":"BIOLOGICAL","name":"1b - rMenB+OMV NZ and routine vaccines","otherNames":[]},{"type":"BIOLOGICAL","name":"2a - Routine and rMenB+OMV NZ vaccines","otherNames":[]},{"type":"BIOLOGICAL","name":"2b - rMenB+OMV NZ and routine vaccines","otherNames":[]},{"type":"BIOLOGICAL","name":"3a - rMenB+OMV NZ and routine vaccines","otherNames":[]},{"type":"BIOLOGICAL","name":"3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations","otherNames":[]},{"type":"BIOLOGICAL","name":"4a- rMenB+OMV NZ and routine vaccines","otherNames":[]},{"type":"BIOLOGICAL","name":"4b - rMenB+OMV NZ and routine vaccines","otherNames":[]}],"arms":[{"label":"12B12M (1a)","type":"EXPERIMENTAL"},{"label":"12B13M (1b)","type":"EXPERIMENTAL"},{"label":"12M13B15B (2a)","type":"EXPERIMENTAL"},{"label":"12M12B14B (2b)","type":"EXPERIMENTAL"},{"label":"12B12M (3a)","type":"EXPERIMENTAL"},{"label":"12B13M (3b)","type":"EXPERIMENTAL"},{"label":"12B12M_C (4a)","type":"EXPERIMENTAL"},{"label":"12B13M_C (4b)","type":"EXPERIMENTAL"}],"summary":"The proposed study is an Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers","primaryOutcome":{"measure":"Percentages of Subjects With Serum Bactericidal Antibody Titers â‰¥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination","timeFrame":"one month after the booster (fourth) dose","effectByArm":[{"arm":"12B12M (1a)","deltaMin":81,"sd":null},{"arm":"12B13M (1b)","deltaMin":82,"sd":null}],"pValues":[]},"eligibility":{"minAge":"365 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":59,"countries":["Austria","Czechia","Finland","Germany","Italy"]},"refs":{"pmids":["31110098","23324563"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":765},"commonTop":["Injection site pain","Irritability","Injection site erythema","Pyrexia","Injection site induration"]}}